Rare bi-allelic loss-of-function variants in the LRRK2 kinase cause interstitial lung disease

This study identifies that rare bi-allelic loss-of-function variants in the LRRK2 gene cause a recessive Mendelian form of interstitial lung disease characterized by lung fibrosis and alveolar type 2 cell dysfunction, distinguishing it from the Parkinson's disease associated with heterozygous activating variants.

The Gist

The Big Picture: A Broken "Quality Control" Machine in the Lungs

Imagine your lungs are a busy factory that constantly produces a special, slippery foam called surfactant. This foam is essential because it keeps the tiny air sacs in your lungs from sticking together and collapsing when you breathe out.

Inside the cells that make this foam (called Alveolar Type 2 cells), there is a very important machine called LRRK2. Think of LRRK2 as the foreman or the quality control manager of this factory. Its job is to organize the delivery trucks (vesicles) that carry the foam ingredients, ensuring they are packed correctly and delivered to the right place.

Usually, when people hear about LRRK2, they think of Parkinson's disease. In that case, the foreman is too active (like a manager who is micromanaging everything), which causes problems in the brain.

This paper discovers a completely different problem: What happens if the foreman is missing entirely?

The Discovery: Two Brothers with a Broken Gene

The researchers found two brothers who suffered from severe, progressive lung scarring (a condition called Interstitial Lung Disease, or ILD). They were tired, short of breath, and eventually needed a lung transplant.

When they looked at the brothers' DNA, they found a "typo" in the instruction manual for the LRRK2 machine. Both brothers had two broken copies of this gene (one from mom, one from dad). This meant they had zero working LRRK2 machines in their bodies.

• The Analogy: Imagine a factory where the foreman is missing. The delivery trucks get lost, the packages (surfactant) are crumpled or thrown in the wrong bins, and the factory floor becomes a chaotic mess.
• The Result: Because the "surfactant factory" couldn't work, the lung cells got damaged, the air sacs collapsed, and the lungs tried to heal by forming scar tissue (fibrosis). This is what caused the brothers' lung failure.

The "Goldilocks" Rule: One Copy is Fine, Zero is Bad

The study also looked at the brothers' parents and a healthy sister. They each had one broken copy and one working copy of the gene.

• The Finding: The parents and the sister had perfectly healthy lungs.
• The Lesson: This proves that having 50% of the foreman (one working gene) is enough to keep the factory running smoothly. You only get sick if you have zero working copies. This is why the disease is called "recessive"—you need two bad copies to get sick.

What Happens Inside the Cells?

When the researchers looked at the brothers' lung tissue under a microscope, they saw the "chaos" predicted by the broken foreman theory:

1. The Trucks are Stuck: The cells were swollen and filled with weird, empty bubbles (vacuoles).
2. The Foam is Wrong: The surfactant proteins were floating around in the wrong places instead of being packed into neat delivery packages (lamellar bodies).
3. The Factory is Burning Out: The cells were so stressed that they started changing shape, turning into a different, scar-producing type of cell. This is what led to the scarring (fibrosis) in their lungs.

Checking Other People

The researchers didn't stop at just these two brothers. They searched through huge databases of genetic information from thousands of other people. They found a few more individuals who also had two broken copies of the LRRK2 gene.

• The Result: Every single person with two broken copies had some form of lung disease.
• The Contrast: People with one broken copy (who are common in the general population) do not have lung disease.

Why This Matters (According to the Paper)

The paper concludes that LRRK2 is a "double-edged sword":

• Too much activity (Gain-of-function) causes Parkinson's disease.
• No activity at all (Loss-of-function) causes severe lung scarring.

The authors note that because LRRK2 is a target for drugs being developed to treat Parkinson's (drugs that try to slow down or stop the machine), this discovery is a safety warning. It suggests that if you completely shut down LRRK2 in a patient, you might accidentally cause lung damage, just like the brothers in this study.

In summary: This paper identifies a rare genetic condition where having no "foreman" (LRRK2) in the lung cells causes the factory to collapse, leading to severe scarring. It proves that while having half a foreman is safe, having none is dangerous for the lungs.

Technical Summary

Technical Summary: Rare biallelic loss-of-function variants in the LRRK2 kinase cause interstitial lung disease

Problem Statement
Leucine-rich repeat kinase 2 (LRRK2) is a multifunctional protein kinase known primarily for its role in Parkinson's disease (PD), where pathogenic gain-of-function (GoF) variants are a major genetic cause. Consequently, LRRK2 is a target for therapeutic inhibition. While heterozygous loss-of-function (LoF) variants in humans appear tolerated without overt pulmonary disease, the consequences of biallelic (homozygous or compound heterozygous) LoF in humans remain undefined. Preclinical studies in rodents and non-human primates suggest that LRRK2 inhibition or knockout leads to pulmonary alveolar type 2 (AT2) cell abnormalities, impaired lamellar body (LB) homeostasis, and early interstitial remodeling, raising concerns that systemic LRRK2 inhibition could predispose patients to interstitial lung disease (ILD). This study seeks to define the human phenotype associated with biallelic LRRK2 LoF.

Methodology
The study employed an integrated approach combining clinical phenotyping, genetic analysis, and molecular characterization:

• Clinical Cohort: The primary focus was a consanguineous family with two affected brothers presenting with early-onset ILD. Additional cases were identified by querying large-scale public genetic databases (TOPMed and the NIH "All of Us" Research Program) for ILD patients carrying biallelic LRRK2 LoF variants.
• Genetic Analysis: Exome sequencing (ES) and whole-genome sequencing (WGS) were used to identify variants. Sanger sequencing confirmed genotypes. Variants were assessed for rarity in the gnomAD database.
• Histopathology and Imaging: High-resolution computed tomography (HRCT) and chest radiographs were analyzed. Lung tissue from explants (index patient) and biopsies (affected brother) underwent histological examination, including electron microscopy and immunohistochemistry.
• Molecular and Cellular Assays:
  • Biomarker Analysis: Peripheral blood neutrophils were analyzed via targeted mass spectrometry to measure LRRK2 protein abundance and phosphorylation of LRRK2 (Ser910, Ser935) and its substrate Rab10 (Thr73). Urinary bis(monoacylglycero)phosphate (BMP) levels were measured as a biomarker of lysosomal dysfunction.
  • Cellular Imaging: Super-resolution microscopy was used on lung tissue to visualize the localization of surfactant proteins (pro-SFTPC, mature SFTPB) and lamellar body markers (ABCA3, LAMP3).
  • In Vitro Functional Assays: HEK293 cells were transfected with constructs expressing the identified nonsense variants to assess protein truncation and kinase activity (Rab10 phosphorylation).

Key Results

• Clinical Phenotype: Two brothers with a homozygous nonsense variant (c.4969C>T; p.Gln1657*) presented with progressive dyspnea, restrictive lung function, and digital clubbing. Imaging revealed emphysematous changes, bronchiolectasis, and ground-glass opacities. Histopathology showed features of usual interstitial pneumonia (UIP), including fibroblastic foci, honeycombing, and enlarged, vacuolated AT2 cells.
• Genetic Findings: The index family carried a homozygous LRRK2 nonsense variant truncating the protein upstream of the kinase domain. This variant is extremely rare in the general population and observed only in the heterozygous state in gnomAD.
• Molecular Characterization:
  • Loss of Protein and Activity: In homozygous patients, LRRK2 protein was undetectable in neutrophils. Consequently, phosphorylation of Rab10 (Thr73) and LRRK2 autophosphorylation sites (Ser910, Ser935) were absent. Urinary BMP levels were significantly reduced, confirming systemic pathway inactivation. Heterozygous carriers retained detectable protein and phosphorylation.
  • AT2 Cell Dysfunction: Lung tissue from affected individuals showed mislocalization of surfactant proteins (pSFTPC, mSFTPC) and disrupted lamellar body structure (heterogeneous ABCA3/LAMP3 staining). This recapitulated the "enlarged, vacuolated AT2 cell" phenotype seen in LRRK2 knockout animals.
  • Fibrotic Transition: Abundant pro-fibrotic epithelial cells (marked by KRT8 and KRT17 expression) were found in fibrotic regions, indicating a transition from functional AT2 cells to a pro-fibrotic state.
• Additional Cases: The study identified three additional unrelated individuals with ILD carrying biallelic LRRK2 LoF variants (one homozygous nonsense, one compound heterozygous with a splice donor and nonsense variant). Functional assays confirmed these variants result in truncated proteins with abolished kinase activity.

Significance and Claims
The paper claims to provide the first human genetic evidence that biallelic LRRK2 loss-of-function causes a Mendelian form of interstitial lung disease. The findings establish a dose-dependent role for LRRK2 in pulmonary homeostasis, where complete loss of function leads to surfactant processing defects, AT2 cell dysfunction, and subsequent lung fibrosis.

The authors state these results have two primary implications:

1. Safety of Therapeutics: The findings inform the therapeutic window and tolerability risks of systemically administered LRRK2-targeted strategies (such as kinase inhibitors or degraders) currently in development for Parkinson's disease. While heterozygous reduction appears safe, complete inhibition may pose a risk for pulmonary toxicity.
2. Disease Mechanism: The study expands the phenotypic spectrum of LRRK2-associated disease beyond PD, demonstrating that both gain-of-function (causing PD) and loss-of-function (causing ILD) drive distinct human pathologies. It suggests that activation of the LRRK2 pathway may warrant exploration as a therapeutic strategy for fibrotic lung disease.

The paper concludes that human genetics can effectively inform the safety and targeting of biologically tractable pathways across different organ systems.